To include your compound in the COVID-19 Resource Center, submit it here.

Lyxumia meets diabetes endpoint

Sanofi (Euronext:SAN; NYSE:SNY) and partner Zealand Pharma A/S (CSE:ZEAL) said Lyxumia lixisenatide

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE